We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sequenom, Inc. Files Motion for Preliminary Injunction Against Aria Diagnostics

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sequenom, Inc. Files Motion for Preliminary Injunction Against Aria Diagnostics"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Sequenom's request for preliminary injunction follows the lawsuit filed on January 24, 2012, in the United States District Court for the Southern District of California, which alleges that Aria infringes U.S. Patent No. 6,258,540 ("'540 patent"). Sequenom is requesting that the district court quickly intervene to stop Aria Diagnostics' continued infringement of the '540 patent.

Sequenom Center for Molecular Medicine (Sequenom CMM) was the first to market a non-invasive prenatal diagnostics laboratory developed test (LDT) for chromosomal aneuploidy. Sequenom CMM's MaterniT21(TM) PLUS LDT detects a genetic chromosomal anomaly known as Trisomy 21, the most common cause of Down syndrome, and also detects trisomies 18 and 13. The test is available to physicians upon request in major metropolitan regions across the United States.